Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zabadinostat
- Development stage
- Phase 2
- Lead developer
- IngeneOx Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Zabadinostat (formerly CXD101 and AZD-9468) is an orally bioavailable, Class I selective histone deacetylase (HDAC) inhibitor being developed by Celleron Therapeutics. It specifically targets HDAC1, HDAC2, and HDAC3 with high potency, which are enzymes involved in the epigenetic regulation of gene expression. By inhibiting these targets, zabadinostat is designed to alter the transcriptional profile of cancer cells, leading to cell cycle arrest, apoptosis, and potentially reversing immune evasion. The drug is primarily being investigated for the treatment of advanced or metastatic cancers, including microsatellite-stable (MSS) colorectal cancer, where it is evaluated in combination with immune checkpoint inhibitors like nivolumab to sensitize tumors that are typically resistant to immunotherapy.
- Other names
- zabadinostatHdac inhibitor cxd101Hdac-in-4Hdac-in4Hdac-in 4
02
Targets
HDAC1 (Histone Deacetylase 1)HDAC8 (Histone Deacetylase 8)
Beyond the preview
Go deeper on zabadinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zabadinostat.